Takeda Pharmaceutical Company Explained

Takeda Pharmaceutical Company Limited[1]
Native Name:武田薬品工業株式会社
Native Name Lang:ja
Romanized Name:Takeda Yakuhin Kōgyō kabushiki gaisha
Former Name:Chobei Takeda & Co., Ltd. (1925–1943)
Takeda Pharmaceutical Industries, Ltd. (English name only 1943–1961)
Takeda Chemical Industries, Ltd. (English name only 1961–2004)[2]
Type:Public KK
Foundation:Doshomachi, Osaka, Japan
Founder:Chobei Takeda I
Location City:Nihonbashi, Chuo, Tokyo
Location Country:Japan
Key People:Yasuchika Hasegawa
(Chairman of the Board)
Christophe Weber[3]
(President & CEO)
Industry:Pharmaceuticals
Revenue: (FY 2022)[4]
Operating Income: (FY 2022)
Net Income: (FY 2022)
Assets: (FY 2022)
Equity: (FY 2022)
Owners:
Num Employees:
  • 49,578 (2019)
  • 18,378 in United States [6]
  • 5,350 in Japan[7]

The pronounced as /ja/ is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year.[8] The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo.[9] [10] In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.[11] As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.[12]

History

Founding and initial acquisitions (1781–2010)

Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925.[13]

One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It was launched in 1999.[14]

In February 2005, Takeda acquired San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for US$270 million.[15]

In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market.[16] In April, Takeda acquired Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for US$8.8 billion.[17] The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary. In May, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.[18]

Further expansion and research (2011–present)

In September 2011, Takeda acquired Nycomed for €9.6 billion.[19]

In May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million.[20] In June, Takeda announced it would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million.[21]

In September 2014, Takeda announced it would team up with BioMotiv to identify and develop new compounds over a five-year period, worth approximately US$25 million.[22] On 30 September 2014, Takeda announced it would expand a collaboration with MacroGenics, valued up to US$1.6 billion. The collaboration focused on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is indicated for lupus and rheumatoid arthritis.[23]

In 2015, Takeda sold its respiratory drugs business to AstraZeneca for $575 million (about £383 million), which included roflumilast and ciclesonide.[24] On November, the U.S. Food and Drug Administration approved Ixazomib developed by Takeda for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.[25]

In December 2016, the company spun out its neuroscience research division into Cerevance, a joint venture along with Lightstone Ventures.[26]

In February 2017, Takeda acquired Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions.[27]

In January 2018, the company acquired stem cell therapy developer TiGenix for up to €520 million ($632 million).[28]

In January 2019, Takeda acquired Shire for more than .[29] [30] In October, Takeda announced it had sold a portfolio of over-the-counter and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino International for more than $200 million.[31] [32]

In January 2020, Takeda announced a research partnership with the Massachusetts Institute of Technology (MIT) to advance discoveries in artificial intelligence and health. The MIT-Takeda Program is housed in the MIT Jameel Clinic, and is led by Professor James J. Collins, with a steering committee led by Professor Anantha P. Chandrakasan, dean of the MIT School of Engineering, and Anne Heatherington, senior vice president and head of Data Sciences Institute (DSI) at Takeda.[33] [34] [35] In March 2020, Takeda announced that it has entered into an exclusive agreement to divest a portfolio of non-core products in Latin America to Hypera S.A. for a total value of $825 million.[36]

In March 2021, the company announced it would acquire Maverick Therapeutics, Inc. and its two major programs TAK-186 (MVC-101) in trials for the treatment of EGFR-expressing tumours and TAK-280 (MVC-280) for use in the treatment of patients with B7H3-expressing tumors.[37] In October, they acquired GammaDelta Therapeutics and its gamma delta (γδ) T cell immunotherapy programme.[38] [39]

In January 2022, Takeda announced it would exercise its option to acquire Adaptate Biotherapeutics and its antibody-based γδ T cell technology, reuniting Adaptate and its former parent company, GammaDelta Therapeutics, in a single organisation.[40] [41] In December of the same year, the company announced it would acquire Nimbus Lakshmi, Inc. and its lead compound NDI-034858 which is an allosteric TYK2 inhibitor, from Nimbus Therapeutics, LLC for up to $6 billion.[42] [43]

In February 2024, Takeda Pharmaceutical gained approval from the FDA for Eohilia, the first oral approval for allergic inflammation of the esophagus for patients 11 years and older. At the time of the announcement, the treatment Dupixent from Sanofi and Regeneron was the only alternative.[44]

In May 2024, Takeda announced it would be laying off 641 employees based in Massachusetts between July 2024 and March 2025 as part of a restructuring. It was expected to affect 495 people based in Cambridge and 146 people in Lexington.[45]

TAP Pharmaceuticals (1977–2008)

See main article: TAP Pharmaceuticals. In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals.[46] Through TAP Pharmaceuticals Takeda and Abbott launched blockbuster drugs Lupron (leuprorelin), in 1985,[47] then Prevacid (lansoprazole), in 1995.[48]

In 2001, TAP's illegal marketing of Lupron resulted in both civil and criminal charges by the U.S. Department of Justice and the Illinois attorney general for federal and state medicare fraud. TAP was fined $875 million, then reported as the largest pharmaceutical settlement in history.[49] [50]

In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals.[51] The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff.[52] Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees.[53]

Acquisition history

Divestments

In May 2019, Takeda sold its Xiidra dry-eye drug business to Novartis for $5.3 billion, $3.4 billion upfront and up-to $1.9 billion in sales milestones.[54] [55]

In November 2019, Takeda entered an agreement to sell its over-the-counter and prescription drugs businesses in Russia, Georgia, Armenia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan to Stada Arzneimittel for $660 million.[56]

In June 2020, Takeda announced that it was divesting 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea's Celltrion in a deal worth $278 million.[55] [57] [58] [59]

Also in 2020, Takeda sold TachoSil to Corza Health, Inc. for €350 million.[60]

Locations

Takeda operates two primary bases in Japan in Osaka and Tokyo. Its United States subsidiary is based in Cambridge, Massachusetts, and all Global Operations outside Japan and the U.S. are based in Opfikon (Zurich), Switzerland.The company maintains research and development sites in Japan, the United States, the United Kingdom and Singapore, with manufacturing facilities across the globe.

Lawsuits

In April 2015 Takeda agreed to pay a settlement of $2.37 billion to an estimated 9,000 people who submitted claims alleging that pioglitazone was responsible for giving them bladder cancer. The company said the decision is expected to resolve the “vast majority” of these cases. Takeda will put the money into a settlement fund if 95 percent of plaintiffs agree to the accord, according to which each claimant would get an average $267,000. However, the exact amount for each plaintiff will be evaluated based on cumulative dosage, extent of injuries and history of smoking.[61] In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda hid the cancer risks of their diabetes medicine,[62] but the amount was later reduced to $26 million by a judge who deemed the charge excessive.[63]

Public–private engagement

Activism

Takeda is a corporate partner of Human Rights Campaign, a large LGBT advocacy organization.[64]

Notes and References

  1. Web site: Company Facts | Takeda. www.takeda.com.
  2. Web site: The History of Takeda – 1781 to 1944 | Takeda.
  3. News: Japan drugmaker Takeda says Christophe Weber to become CEO April 1 . Chris Gallagher . Muralikumar Anantharaman . . 2015-03-15 . 2015-04-20.
  4. Web site: Financial Results for Fiscal 2023. Takeda Pharmaceutical Company Limited. December 27, 2023. May 11, 2023.
  5. Web site: Share Data | Takeda.
  6. Web site: Working at Takeda Pharmaceuticals NA.
  7. Web site: Takeda offers early retirement to workers as young as 30. Nikkei Asia.
  8. Web site: Financial Results for Fiscal 2012. Takeda Pharmaceutical Company Limited. 2013-06-13. 2013-05-09.
  9. "FAQ." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Q : Where is Takeda located? A : The Head Office is located in Osaka, Japan, and the Tokyo Head Office is located in Tokyo, Japan."
  10. "Overview." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Headquarters Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645" and "Tokyo Head Office 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668"
  11. News: 2012-02-06 . 100 Best Companies to Work For 2012 . 2018-03-29 . Fortune.
  12. Web site: Christophe Weber . live . https://web.archive.org/web/20240415202046/https://www.takeda.com/about/leadership/christophe-weber/ . 2024-04-15 . 2024-04-15 . Takeda.
  13. Web site: Du . Lisa . 2018-12-12 . Daring Deal by French CEO Sets Japan's Takeda on Global Path . subscription . live . https://web.archive.org/web/20210122052341/https://www.bloomberg.com/news/articles/2018-12-12/daring-deal-by-french-ceo-sets-japan-s-takeda-on-global-path . 2021-01-22 . 2020-02-20 . Bloomberg.com.
  14. Web site: Immediate Actos Appeal Will Resolve Uncertainty, Takeda Says . subscription . 2020-02-20 . news.bloomberglaw.com . en.
  15. Web site: 2005-02-08 . Japan's Takeda to Acquire Syrrx . live . https://web.archive.org/web/20200220202859/https://www.latimes.com/archives/la-xpm-2005-feb-08-fi-syrxx8-story.html . 2020-02-20 . 2020-02-20 . Los Angeles Times . en-US.
  16. Web site: Takeda, Amgen in exclusive tie-up for Japanese market . MarketWatch . 2008-02-04 . 2010-09-18.
  17. News: Takeda to buy Millennium Pharma for $8.8 billion. 2008-04-10. Reuters. 2020-02-20. en.
  18. Web site: Alnylam Signs Potential $1B RNAi Agreement with Takeda. bioworld.com. en. 2020-02-20.
  19. Web site: Takeda to Buy Nycomed for $13.7 Billion. Dealbook. 2011-05-19. DealBook. en. 2020-02-20.
  20. Web site: Hirschler, Ben. 2012-05-25. Farmacêutica Takeda comprará Multilab por até R$ 540 mi. 2013-01-27. Grupo Abril. Exame. pt.
  21. Web site: Takeda to acquire URL Pharma for $800m. 11 April 2012. en-GB. 2020-02-20. 2020-02-20. https://web.archive.org/web/20200220203615/https://www.pharmaceutical-technology.com/uncategorised/newstakeda-to-acquire-url-pharma-for-800m/. dead.
  22. News: Takeda, BioMotiv Launch $25M Drug Development Partnership. 2014-09-26. Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc.. 2015-04-23.
  23. News: Takeda, MacroGenics Launch Up to $1.6B Expansion of DART Collaboration. 2014-09-30. Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc.. 2015-04-23.
  24. Julia Bradshaw for The Daily Telegraph, 16 December 2015. AstraZeneca to buy Takeda's lung business for £383m.Accessed: 17 December 2015.
  25. Web site: Ninlaro (ixazomib) FDA Approval History. Drugs.com. en. 2020-02-20.
  26. Web site: Takeda Spins Out Research Team into Neuroscience Startup. 2016-12-02.
  27. Web site: Takeda to Acquire ARIAD Pharmaceuticals for $5.2B. 2017-01-09.
  28. Web site: Takeda to Acquire TiGenix for €520M. 2018-01-05.
  29. News: Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire. Du. Lisa. 8 May 2018. 6 July 2019. Bloomberg. Takahashi. Maiko. en. subscription.
  30. Philippidis. Alex. 1 July 2019. Top 10 M&A Deasl of January - June 2019. Genetic Engineering & Biotechnology News. And it didn't include earlier-announced deals completed in 2019, such as Takeda Pharmaceutical's £46 billion ($58.6 billion) purchase of Shire..
  31. News: Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino. 2019-10-15. Reuters. 2019-10-15. en.
  32. Web site: Takeda wraps 30 emerging markets drugs in $200M selloff to Swiss pharma Acino. FiercePharma. 15 October 2019. en. 2019-10-15.
  33. Web site: MIT School of Engineering and Takeda join to advance research in artificial intelligence and health. 2020-11-13. MIT News Massachusetts Institute of Technology. 6 January 2020 . en.
  34. Web site: analytica. TOKYO. 2020-01-07. 武田薬品とMITがAI研究を推進するプログラムを発表 医療とAIのニュース・最新記事 - The Medical AI Times. 2020-11-13. The AI Times. ja.
  35. Web site: 2020-01-06. MIT, Takeda collaborate on new healthcare AI applications. 2020-11-13. Healthcare IT News. en.
  36. Web site: Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD. BioSpace. en-US. 2020-03-03.
  37. News: Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio. BioSpace.
  38. Web site: Takeda Snaps up Partner GammaDelta to Bolster Oncology Pipeline.
  39. Web site: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors. BioSpace.
  40. Web site: Takeda Augments IO Portfolio with Third Build-to-Buy Acquisition in a Year. BioSpace.
  41. Web site: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors. BioSpace.
  42. Web site: Takeda to Acquire Nimbus Therapeutics' Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases. BioSpace.
  43. Web site: Takeda Bets $4B Upfront on Nimbus' TYK2 Inhibitor. BioSpace.
  44. Web site: Roy . Sriparna . February 12, 2024 . Takeda's treatment becomes first oral therapy for esophageal condition in US . February 12, 2024 . Reuters.
  45. Web site: Saltzmam . Jonathan . May 24, 2024 . Drug giant Takeda plans more than 640 layoffs in Massachusetts . 2024-05-25 . BostonGlobe.com . en-US.
  46. Web site: 2017-07-18. Takeda shrinks its Deerfield workforce, as it adds in Boston. 2020-02-20. Crain's Chicago Business. en.
  47. News: Japson. Bruce. Apr 29, 2001. The Lupron loophole: Cancer drug strikes it rich. Chicago tribune. 19 June 2021.
  48. Web site: Takeda Pharmaceutical to Pay Abbott Laboratories up to $1.5B in Venture Split. 2020-02-20. FierceBiotech. 20 March 2008. en.
  49. News: Petersen. Melody. Oct 4, 2001. 2 Drug Makers to Pay $875 Million to Settle Fraud Case. The New York Times. June 19, 2021.
  50. Web site: Oct 3, 2001. Press Release: TAP Pharmaceutical Products Inc. and Seven Others Charged with Health Care Crimes. June 19, 2021. US Department of Justice.
  51. Web site: 2008-03-19. Abbott, Takeda to end joint venture. 2020-02-20. Crain's Chicago Business. en.
  52. News: Wang. Shirley S.. 2008-03-20. Abbott, Takeda to End Joint Venture. en-US. Wall Street Journal. 2020-02-20. 0099-9660.
  53. Web site: Marrazzo. Amanda. 2008-05-15. Featured Articles From The Chicago Tribune. 2010-09-18. Archives.chicagotribune.com.
  54. Web site: Novartis to buy Takeda's eyedrop unit for $5.3bn. 2020-06-12. Nikkei Asian Review. en-GB.
  55. Web site: Takeda continues post-Shire selloff, inching closer to $10B goal. 2020-06-12. Endpoints News. en.
  56. Web site: Takeda sells Russian assets in $660m deal to cut Shire debt. 2020-06-12. Nikkei Asian Review. en-GB.
  57. Web site: Takeda sells 18 drugs to South Korea's Celltrion in $278m deal. 2020-06-12. Nikkei Asian Review. en-GB.
  58. News: 2020-06-11. BRIEF-Takeda Pharmaceutical Enters Into Agreement To Divest Portfolio Of Select Non-Core OTC And Prescription Pharmaceutical Products. en. Reuters. 2020-06-12.
  59. News: 2020-06-11. Takeda to Divest OTC and Select Non-core Assets in Asia Pacific to Celltrion for up to $278 Million USD Financial Post. Financialpost. 2020-06-12. en-CA.
  60. Web site: Takeda to Divest TachoSil® to Corza Health for €350 Million . 2023-04-09 . www.takeda.com . en.
  61. Web site: Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos. 29 April 2015. The New York Times.
  62. Web site: Takeda, Lilly Jury Awards $9 Billion Over Actos Risks. Jef. Feeley. Kanoko. Matsuyama. 9 April 2014. bloomberg.com.
  63. Web site: Japan's Takeda Agrees To $2.4B Settlement In Diabetes Drug Actos Lawsuit Over Cancer Risk Allegations. International Business Times. 29 April 2015.
  64. Web site: Corporate Partners . live . https://web.archive.org/web/20220714072833/https://www.hrc.org/about/corporate-partners . 2022-07-14 . 2022-07-14 . Human Rights Campaign.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Takeda Pharmaceutical Company".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.